2019
Asrani K, Murali S, Lam B, Na CH, Phatak P, Sood A, Kaur H, Khan Z, Noë M, Anchoori RK, Talbot CC Jr, Smith B, Skaro M, Lotan TL. mTORC1 feedback to AKT modulates lysosomal biogenesis through MiT/TFE regulation. J Clin Invest. 2019 Dec 2;129(12):5584-5599. doi: 10.1172/JCI128287. PubMed PMID: 31527310; PubMed Central PMCID: PMC6877313.
Faisal FA, Lotan TL. The Genomic and Molecular Pathology of Prostate Cancer: Clinical Implications for Diagnosis, Prognosis, and Therapy. Adv Anat Pathol. 2019 Sep 9;. doi: 10.1097/PAP.0000000000000245. [Epub ahead of print] PubMed PMID: 31503032.
Khani F, Wobker SE, Hicks JL, Robinson BD, Barbieri CE, De Marzo AM, Epstein JI, Pritchard CC, Lotan TL. Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations. J Pathol. 2019 Sep;249(1):79-89. doi: 10.1002/path.5283. Epub 2019 May 24. PubMed PMID: 30993692.
Faisal FA, Tosoian JJ, Han M, Macura KJ, Pavlovich CP, Lotan TL. Clinical, Pathological and Oncologic Findings of Radical Prostatectomy with Extraprostatic Extension Diagnosed on Preoperative Prostate Biopsy. J Urol. 2019 May;201(5):937-942. doi: 10.1016/j.juro.2018.10.023. PubMed PMID: 30414957.
Lotan TL, Kaur HB, Alharbi AM, Pritchard CC, Epstein JI. DNA damage repair alterations are frequent in prostatic adenocarcinomas with focal pleomorphic giant-cell features. Histopathology. 2019 May;74(6):836-843. doi: 10.1111/his.13806. Epub 2019 Apr 1. PubMed PMID: 30636012; PubMed Central PMCID: PMC6476659.
Faisal FA, Kaur HB, Tosoian JJ, Tomlins SA, Schaeffer EM, Lotan TL. SPINK1 expression is enriched in African American prostate cancer but is not associated with altered immune infiltration or oncologic outcomes post-prostatectomy. Prostate Cancer Prostatic Dis. 2019 Mar 8;. doi: 10.1038/s41391-019-0139-0. [Epub ahead of print] PubMed PMID: 30850708.
Kaur HB, Lu J, Guedes LB, Maldonado L, Reitz L, Barber JR, De Marzo AM, Tomlins SA, Sfanos KS, Eisenberger M, Schaeffer EM, Joshu CE, Lotan TL. TP53 missense mutation is associated with increased tumor-infiltrating T-cells in primary prostate Cancer. Hum Pathol. 2019 Mar 6;. doi: 10.1016/j.humpath.2019.02.006. [Epub ahead of print] PubMed PMID: 30851334.
Guedes LB, Morais CL, Fedor H, Hicks J, Gurel B, Melamed J, Lee P, Gopalan A, Knudsen BS, True LD, Scher HI, Fine SW, Trock BJ, De Marzo AM, Lotan TL. Effect of Preanalytic Variables on an Automated PTEN Immunohistochemistry Assay for Prostate Cancer. Arch Pathol Lab Med. 2019 Mar;143(3):338-348. doi: 10.5858/arpa.2018-0068-OA. Epub 2018 Oct 8. PubMed PMID: 30295067.
2018
Kaur HB, Guedes LB, Lu J, Maldonado L, Reitz L, Barber JR, De Marzo AM, Tosoian JJ, Tomlins SA, Schaeffer EM, Joshu CE, Sfanos KS, Lotan TL. Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer. Mod Pathol. 2018 Oct;31(10):1539-1552. doi: 10.1038/s41379-018-0083-x. Epub 2018 May 30. PubMed PMID: 29849114; PubMed Central PMCID: PMC6168349.
Torres A, Alshalalfa M, Davicioni E, Gupta A, Yegnasubramanian S, Wheelan SJ, Epstein JI, De Marzo AM, Lotan TL. ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63. Prostate. 2018 Sep;78(12):896-904. doi: 10.1002/pros.23646. Epub 2018 May 15. PubMed PMID: 29761525; PubMed Central PMCID: PMC6818503.
Kang H, Antonarakis ES, Luo J, Zheng Q, Rooper L, De Marzo AM, Westra WH, Lotan TL. Detection of AR-V7 transcript with RNA in situ hybridization in human salivary duct cancer. Oral Oncol. 2018 Sep;84:134-136. doi: 10.1016/j.oraloncology.2018.06.026. Epub 2018 Jun 28. PubMed PMID: 30122219.
Maughan BL, Guedes LB, Boucher K, Rajoria G, Liu Z, Klimek S, Zoino R, Antonarakis ES, Lotan TL. p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2018 Jun;21(2):260-268. doi: 10.1038/s41391-017-0027-4. Epub 2018 Jan 4. PubMed PMID: 29302046.
Jamaspishvili T, Berman DM, Ross AE, Scher HI, De Marzo AM, Squire JA, Lotan TL. Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol. 2018 Apr;15(4):222-234. doi: 10.1038/nrurol.2018.9. Epub 2018 Feb 20. Review. PubMed PMID: 29460925.
2017
Guedes LB, Antonarakis ES, Schweizer MT, Mirkheshti N, Almutairi F, Park JC, Glavaris S, Hicks J, Eisenberger MA, De Marzo AM, Epstein JI, Isaacs WB, Eshleman JR, Pritchard CC, Lotan TL. MSH2 Loss in Primary Prostate Cancer. Clin Cancer Res. 2017 Nov 15;23(22):6863-6874. doi: 10.1158/1078-0432.CCR-17-0955. Epub 2017 Aug 8. PubMed PMID: 28790115; PubMed Central PMCID: PMC5690834.
Tsai HK, Lehrer J, Alshalalfa M, Erho N, Davicioni E, Lotan TL. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma. BMC Cancer. 2017 Nov 13;17(1):759. doi: 10.1186/s12885-017-3729-z. PubMed PMID: 29132337; PubMed Central PMCID: PMC5683385.
Asrani K, Sood A, Torres A, Georgess D, Phatak P, Kaur H, Dubin A, Talbot CC Jr, Elhelu L, Ewald AJ, Xiao B, Worley P, Lotan TL. mTORC1 loss impairs epidermal adhesion via TGF-β/Rho kinase activation. J Clin Invest. 2017 Nov 1;127(11):4001-4017. doi: 10.1172/JCI92893. Epub 2017 Sep 25. PubMed PMID: 28945203; PubMed Central PMCID: PMC5663351.
Guedes LB, Almutairi F, Haffner MC, Rajoria G, Liu Z, Klimek S, Zoino R, Yousefi K, Sharma R, De Marzo AM, Netto GJ, Isaacs WB, Ross AE, Schaeffer EM, Lotan TL. Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer. Clin Cancer Res. 2017 Aug 15;23(16):4693-4703. doi: 10.1158/1078-0432.CCR-17-0257. Epub 2017 Apr 26. PubMed PMID: 28446506; PubMed Central PMCID: PMC5559307.
Tosoian JJ, Almutairi F, Morais CL, Glavaris S, Hicks J, Sundi D, Humphreys E, Han M, De Marzo AM, Ross AE, Tomlins SA, Schaeffer EM, Trock BJ, Lotan TL. Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy. Eur Urol. 2017 May;71(5):697-700. doi: 10.1016/j.eururo.2016.07.026. Epub 2016 Jul 28. PubMed PMID: 27477529; PubMed Central PMCID: PMC5274596.
Torres A, Alshalalfa M, Tomlins SA, Erho N, Gibb EA, Chelliserry J, Lim L, Lam LLC, Faraj SF, Bezerra SM, Davicioni E, Yousefi K, Ross AE, Netto GJ, Schaeffer EM, Lotan TL. Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay. J Mol Diagn. 2017 May;19(3):475-484. doi: 10.1016/j.jmoldx.2017.01.007. Epub 2017 Mar 21. PubMed PMID: 28341589; PubMed Central PMCID: PMC5417038.
2016
Guedes LB, Morais CL, Almutairi F, Haffner MC, Zheng Q, Isaacs JT, Antonarakis ES, Lu C, Tsai H, Luo J, De Marzo AM, Lotan TL. Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer. Clin Cancer Res. 2016 Sep 15;22(18):4651-63. doi: 10.1158/1078-0432.CCR-16-0205. Epub 2016 May 10. PubMed PMID: 27166397; PubMed Central PMCID: PMC5026571.
Morais CL, Guedes LB, Hicks J, Baras AS, De Marzo AM, Lotan TL. ERG and PTEN status of isolated high-grade PIN occurring in cystoprostatectomy specimens without invasive prostatic adenocarcinoma. Hum Pathol. 2016 Sep;55:117-25. doi: 10.1016/j.humpath.2016.04.017. Epub 2016 May 14. PubMed PMID: 27189342; PubMed Central PMCID: PMC4981542.
Ahearn TU, Pettersson A, Ebot EM, Gerke T, Graff RE, Morais CL, Hicks JL, Wilson KM, Rider JR, Sesso HD, Fiorentino M, Flavin R, Finn S, Giovannucci EL, Loda M, Stampfer MJ, De Marzo AM, Mucci LA, Lotan TL. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer. J Natl Cancer Inst. 2016 Feb;108(2). doi: 10.1093/jnci/djv346. Print 2016 Feb. PubMed PMID: 26615022; PubMed Central PMCID: PMC4862436.
2015
Tsai H, Morais CL, Alshalalfa M, Tan HL, Haddad Z, Hicks J, Gupta N, Epstein JI, Netto GJ, Isaacs WB, Luo J, Mehra R, Vessella RL, Karnes RJ, Schaeffer EM, Davicioni E, De Marzo AM, Lotan TL. Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas. Clin Cancer Res. 2015 Dec 15;21(24):5619-29. doi: 10.1158/1078-0432.CCR-15-0744. Epub 2015 Aug 5. PubMed PMID: 26246306; PubMed Central PMCID: PMC4681606.
Morais CL, Herawi M, Toubaji A, Albadine R, Hicks J, Netto GJ, De Marzo AM, Epstein JI, Lotan TL. PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas. Prostate. 2015 Oct;75(14):1610-9. doi: 10.1002/pros.23042. Epub 2015 Jul 14. PubMed PMID: 26178158; PubMed Central PMCID: PMC4537350.
Tan HL, Haffner MC, Esopi DM, Vaghasia AM, Giannico GA, Ross HM, Ghosh S, Hicks JL, Zheng Q, Sangoi AR, Yegnasubramanian S, Osunkoya AO, De Marzo AM, Epstein JI, Lotan TL. Prostate adenocarcinomas aberrantly expressing p63 are molecularly distinct from usual-type prostatic adenocarcinomas. Mod Pathol. 2015 Mar;28(3):446-56. doi: 10.1038/modpathol.2014.115. Epub 2014 Sep 12. PubMed PMID: 25216229; PubMed Central PMCID: PMC4344845.